financing
Quanta Therapeutics Raises $50.7M in Series D Financing
The firm anticipates starting proof-of-concept clinical studies for its two lead KRAS inhibitors by the end of 2024.
Myeloid Therapeutics Closes $73M Financing to Advance Immunotherapy Pipeline
The funds will support clinical development of Myeloid's pipeline of targeted next generation cell- and mRNA-based therapies in cancer indications.
Boundless Bio Closes $100M Series C Financing to Develop Drugs for Oncogene-Amplified Cancers
The funds will allow the firm to advance its lead candidate BBI-355 and its preclinical pipeline of extrachromosomal DNA-directed therapies.
Ray Therapeutics Closes $100M in Oversubscribed Series A Funding Round
The San Diego-based company will use the funds to advance its pipeline of optogenetic therapies for diseases that cause blindness.
MyoGene Bio Nets Additional Investment From CureDuchenne Ventures for CRISPR-Based Treatment
The Los Angeles-based biotech will use the funds to develop a gene editing approach targeting the DMD hotspot region where many disease-linked mutations occur.